neutral
Rubicon Research SME IPO Subscription at 0.21 Times on Day 1

Rubicon Research’s SME IPO saw a muted response, with total subscription at 0.21× as of 1:30 PM. The retail portion was subscribed 0.83×, while the QIB category remained unsubscribed. Market observers attributed the tepid demand to valuation concerns and a narrow investor base, despite the company’s focus on pharmaceutical R&D and contract manufacturing. Analysts expect improved traction in later sessions as institutional investors assess sectoral prospects and listing potential.
Explore:Mutual Fund Home
neutral
Rubicon Research SME IPO Subscription at 0.21 Times on Day 1

Rubicon Research’s SME IPO saw a muted response, with total subscription at 0.21× as of 1:30 PM. The retail portion was subscribed 0.83×, while the QIB category remained unsubscribed. Market observers attributed the tepid demand to valuation concerns and a narrow investor base, despite the company’s focus on pharmaceutical R&D and contract manufacturing. Analysts expect improved traction in later sessions as institutional investors assess sectoral prospects and listing potential.
Explore:Mutual Fund Home
1 min read
69 words

SME IPO sees subdued demand in initial hours.
Rubicon Research’s SME IPO saw a muted response, with total subscription at 0.21× as of 1:30 PM. The retail portion was subscribed 0.83×, while the QIB category remained unsubscribed. Market observers attributed the tepid demand to valuation concerns and a narrow investor base, despite the company’s focus on pharmaceutical R&D and contract manufacturing. Analysts expect improved traction in later sessions as institutional investors assess sectoral prospects and listing potential.

Rubicon Research’s SME IPO saw a muted response, with total subscription at 0.21× as of 1:30 PM. The retail portion was subscribed 0.83×, while the QIB category remained unsubscribed. Market observers attributed the tepid demand to valuation concerns and a narrow investor base, despite the company’s focus on pharmaceutical R&D and contract manufacturing. Analysts expect improved traction in later sessions as institutional investors assess sectoral prospects and listing potential.
Companies:
Rubicon Research
Tags:
SME IPO
pharmaceutical R&D
SME IPO
pharmaceutical R&D
contract manufacturing
retail subscription
QIB participation